WHO Criticizes Trump Vaccine Order, Saying MMR Split Would Increase Injections

Senior World Health Organization officials, including Director-General Tedros Adhanom Ghebreyesus, publicly criticized the Trump administration’s latest effort to reshape U.S. childhood vaccination policy, calling the move politically motivated and at odds with the best available science. The criticism focused on an executive order signed by President Trump on Monday that calls for fewer vaccines to be recommended for all children in the U.S. and for broader use of single-pathogen vaccines instead of combination shots.

Tedros said the order is predicated on the disproven claim that increasing vaccine use is behind rising autism rates in the U.S. He stated that vaccines, including the MMR vaccine, are safe and do not cause autism, adding that delaying vaccines or separating doses unnecessarily does not make vaccination safer and can leave children unprotected.

The policy dispute

The executive order does not itself change vaccination policy, but it signals the Trump administration’s push to reduce the number of routine childhood vaccinations and align the U.S. more closely with peer countries in Europe. STAT reported that its own analysis of other countries’ recommendations suggested the opposite outcome: by lowering the number of recommended vaccinations, the U.S. would become an outlier, as is Denmark, the country the administration seeks to emulate.

That difference is especially visible in the order’s push to move away from combination vaccines. It recommends beginning with the measles, mumps, and rubella shot and then extending the approach to other multi-pathogen vaccines. WHO officials argued that this would add operational friction to a system that currently relies on combination products to reduce the number of injections children receive.

Why WHO objects to splitting MMR

Brigitte Giersing, unit head for vaccine research, development, and policy in WHO’s department of immunization, vaccines and biologicals, said only 15 of WHO’s 194 member states vaccinate against measles, mumps, and rubella using monovalent vaccines; all others use the combined MMR. She said breaking up the current two-dose MMR schedule would increase the number of injections and make the schedule more complex, reducing its acceptability for many parents and physicians.

Jeremy Farrar, WHO’s assistant director-general for health promotion and disease prevention and care, framed the risk in access terms rather than ideology. If families must return to six or seven clinic visits for a vaccine series, he said, many will not come back for all of them, leaving children vulnerable during the period when these diseases can cause serious illness.

Kate O’Brien, director of WHO’s department of immunization, vaccines and biologicals, said the evidence base points in the other direction: making vaccination easier increases coverage. Her argument was that the order would make completion harder without presenting evidence that the change improves safety.

The implementation problem

Even if policymakers wanted to execute the order quickly, the U.S. market is not set up for it. STAT reported that there are currently no monovalent vaccines targeting measles, mumps, and rubella licensed in the U.S. Early indications are that manufacturers are not eager to pursue them because the cost of bringing those products through licensure may not be justified by the expected market.

That creates a more immediate signal for vaccine policy and industry strategy than the political debate alone. The administration is advocating a format change that WHO says would reduce uptake and that manufacturers may see as commercially unattractive. In practice, that combination could slow implementation even before the scientific dispute is resolved.